Jingsong Zhang

Feb 28, 2024 | nature.com | Maha Hussain |Jingsong Zhang

AbstractCirculating biomarkers of bone metabolism are significantly associated with overall survival (OS) in men with advanced prostate cancer. In the SWOG S1216 phase III trial, we showed that elevated bone biomarkers are significantly associated with an increased risk of death in hormone-sensitive prostate cancer (HSPC) regardless of the status of bone metastases, identifying three risk groups with differential OS outcomes based on bone biomarker status.

Sep 20, 2023 | mdpi.com | Lingbin Meng |Yuanquan Yang |Amir Mortazavi |Jingsong Zhang

1. IntroductionProstate cancer is the second-most commonly diagnosed cancer and the fifth leading cause of cancer death globally [1,2]. In 2023, the United States is estimated to see about 268,490 new prostate cancer diagnoses and roughly 34,500 prostate cancer related deaths [1,2], with a 5 year survival rate surpassing 99% for localized cases [3].

Jul 7, 2023 | fal.cn | Jad Chahoud |Alexander Anderson |Jingsong Zhang |Joel Brown

Over the past decade, multiple clinical trials using intermittent therapy, which typically applies on/off treatment cycles after an initial induction period, have been published with mixed but generally unimpressive results.